ArticleCureus2025
Abemaciclib-Associated Panniculitis With Fibrosis: Expanding the Dermatologic Spectrum of Cyclin-Dependent Kinase 4/6 Inhibitors.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has significantly improved outcomes for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, yet its dermatologic side effects remain incompletely characterized. We report a case of a 55-year-old woman on abemaciclib and fulvestrant who developed painful, erythematous nodules that progressed to hyperpigmented plaques with skin retraction, including on the breasts. A biopsy revealed chronic panniculitis with fibrosis, a histopathologic finding not previously associated with CDK4/6 inhibitors. Despite these cutaneous changes, abemaciclib was continued without dose modification, and the lesions remained stable without ulceration. This case expands the known spectrum of skin toxicities linked to CDK4/6 inhibition. It underscores the importance of recognizing panniculitis as a potential immune-mediated adverse event, which, in select cases, may be managed conservatively without interrupting oncologic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.